MRI Illuminates Novel Drug ' s Potential for Relapsing-Remitting MS MRI Illuminates Novel Drug ' s Potential for Relapsing-Remitting MS

MRI findings midway through a 2-year phase 3 trial reveal the promise of ALKS 8700 for reducing gadolinium-enhancing lesions among people with multiple sclerosis.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news